title: [R ± BEACOP for Treating Newly Diagnosed, Moderate and High Risk Diffuse Large B Cell Lymphoma Patients].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of R ± BEACOP protocol on newly diagnosed patients with moderate and high risk diffuse large B-cell lymphoma (DLBCL).
  
  
  METHODS
  The clinical data of 19 newly diagnosed patients with moderate and high risk DLBCL received at least 2 cycles of R ± BEACOP protocol during 2011 to 2014 were collected, their therapeutic efficacy and side effects were evaluated by retrospective analysis.
  
  
  RESULTS
  The overall response rate of 19 assessable patients was 94.7%, including 5 patients (26.3%) in complete remission (CR) and 13 patients (68.4%) in partial remission (PR). The major toxicity was hematologic toxicity and the incidence of grade III-IV hematologic toxicity was 73.7%. Other toxicities were mild and no treatment-related death occurred.
  
  
  CONCLUSIONS
  R ± BEACOP protocol is a effective and safe protocol for the patients with DLBCL which is worth further multicenter prospectively studying in china.
authors.affiliation: Department of Hematology, Peking University Third hospital, Beijing 100191, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Dong
authors.affiliation: Department of Hematology, Peking University Third hospital, Beijing 100191, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Hematology, Peking University Third hospital, Beijing 100191, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Yand
authors.affiliation: Department of Hematology, Peking University Third hospital, Beijing 100191, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhao
authors.affiliation: Department of Hematology, Peking University Third hospital, Beijing 100191, China.
authors.forename: Hong-Mei
authors.initials: HM
authors.lastname: Jing
authors.affiliation: Department of Hematology, Peking University Third hospital, Beijing 100191, China. E-mail: xykbysy@163.com.
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Ke
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D002681:China; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse; D012074:Remission Induction; D012189:Retrospective Studies